NHS Prostate Cancer Genetic Testing: Who Qualifies?
If your dad, brother or grandfather has had prostate cancer, you might have wondered whether it could run in your family.
And if it does, could you qualify for genetic testing on the NHS?
Prostate cancer is common, particularly as men get older. Most cases aren’t caused by an inherited high-risk gene change. But in some families, inherited genes can substantially increase the risk of developing prostate cancer, particularly more aggressive forms.
There’s also something many people don’t realise: some of the same inherited genes linked to breast and ovarian cancer can increase prostate cancer risk.
In this guide, I’ll explain who may qualify for NHS genetic testing, which family histories matter, what to ask your GP and how finding an inherited risk can change screening and prevention.
On this page
Who qualifies for NHS prostate cancer genetic testing?
The NHS has specific eligibility criteria for inherited prostate cancer genetic testing.
In England, these are set out in the NHS National Genomic Test Directory, including a pathway called R430 for inherited prostate cancer.
Testing may be offered in situations such as:
- Prostate cancer diagnosed before age 50, even without a family history.
- Prostate cancer that has spread beyond the prostate, diagnosed before age 60.
- Prostate cancer at any age in someone with Ashkenazi Jewish ancestry.
- Prostate cancer at any age in someone with a grandparent from Whalsay in Shetland.
- Prostate cancer alongside a significant family history, where specialist assessment identifies a sufficiently high likelihood of an inherited cancer-risk variant.
Other NHS genetic testing pathways may apply when prostate cancer occurs alongside breast, ovarian, pancreatic or Lynch syndrome-related cancers in a family.
These examples are based on the NHS England testing criteria. The exact pathway depends on the person’s diagnosis, family history and specialist assessment.
How can prostate cancer be inherited?
Yes. Although most prostate cancers aren’t caused by an inherited high-risk gene change, around 5% are associated with a recognised inherited cancer predisposition syndrome.
The best-known gene is BRCA2.
You may have heard of BRCA genes in connection with breast and ovarian cancer, but inherited BRCA2 changes can also significantly increase the risk of prostate cancer, including more aggressive disease.
Other genes associated with inherited prostate cancer risk include BRCA1, ATM, CHEK2, HOXB13 and some of the genes involved in Lynch syndrome.
Not every genetic change carries the same risk, and finding one doesn’t mean someone will definitely develop cancer.
These genes can be inherited from either parent.
A man could inherit a BRCA2 variant from his mother, even if she has never had breast or ovarian cancer. Equally, a father can pass a BRCA variant to his daughters as well as his sons.
This is why inherited prostate cancer risk isn’t simply a question of how many men in your family have had prostate cancer.
Does being referred mean you’ll definitely get genetic testing?
Not necessarily.
A genetics or hospital specialist may review your family’s cancer history, ages at diagnosis and previous testing before deciding whether NHS genetic testing is appropriate.
If someone in your family has already had prostate cancer, it may be more informative to test that person first.
And even if genetic testing isn’t recommended, a family history assessment can still help you understand your individual risk.
What if the prostate cancer was aggressive?
The type and stage of prostate cancer matter.
Inherited BRCA2 variants are more strongly associated with aggressive prostate cancer than with some slower-growing forms.
If a relative was diagnosed unusually young, developed metastatic prostate cancer or had several related cancers in their family, it’s worth asking whether genetic assessment would be appropriate.
However, not every aggressive prostate cancer automatically qualifies for inherited genetic testing. The specialist will consider the relevant NHS pathway.
Does a family history of prostate cancer mean I should have genetic testing?
Not always, but it can be a reason to ask for an assessment.
Having a father or brother with prostate cancer increases your own risk of developing the disease, particularly when they were diagnosed at a younger age.
For example, if your father developed prostate cancer at 48, that may be more suggestive of an inherited predisposition than a single relative diagnosed in his late eighties.
The number of affected relatives, their ages and the type of prostate cancer also matter.
You don’t have to have prostate cancer yourself to be concerned about inherited risk.
If a relative meets the criteria for NHS genetic testing, identifying a genetic change in them may allow other family members to have a much simpler, targeted test.
If you are unaffected and nobody in your family has had genetic testing, the best first step is often a family history assessment.
And remember, inherited risk can come through women in the family too.
Why do breast, ovarian and pancreatic cancers matter?
This is one of the most important things to understand about inherited prostate cancer risk.
The same inherited BRCA2 gene change can increase the risk of several different cancers.
So when assessing a family history of prostate cancer, doctors should also ask about:
- Breast cancer, including male breast cancer.
- Ovarian cancer.
- Pancreatic cancer.
- Other prostate cancers, particularly those diagnosed young or associated with aggressive disease.
For example, a family where one man developed prostate cancer at 55 and his sister developed breast cancer at 38 may warrant a closer look at inherited risk.
The cancers don’t all need to affect men, and the family history on your mother’s side is just as relevant as your father’s.
Other inherited conditions, including Lynch syndrome, can connect prostate cancer with bowel or womb cancer in some families.
For more information, see our guides to NHS BRCA and breast cancer genetic testing, ovarian cancer genetic testing and pancreatic cancer genetic testing.
Can you qualify for NHS testing because of your ancestry?
Yes. Certain inherited BRCA variants are more common in particular populations, even when there isn’t an obvious family history of cancer.
Jewish ancestry and BRCA testing
Inherited BRCA1 and BRCA2 variants are more common among people with Ashkenazi Jewish ancestry than in the general UK population.
The NHS Jewish BRCA Testing Programme offered testing to eligible adults with Jewish ancestry, including those without a personal or family history of cancer.
The original programme is closed to new registrations, with a longer-term NHS service anticipated in 2027.
You can check the latest information through the NHS Jewish BRCA Testing Programme.
People who have already been diagnosed with prostate cancer may also qualify through existing NHS genetic testing pathways, so they shouldn’t wait for the population programme to reopen before speaking to their cancer team.
Whalsay ancestry and inherited BRCA2 risk
Researchers have identified a particular inherited BRCA2 variant associated with ancestry from Whalsay in Shetland.
This is important because BRCA2 can increase the risk of prostate cancer as well as breast and ovarian cancer.
The NHS inherited prostate cancer testing criteria specifically recognise men with prostate cancer who have at least one grandparent from Whalsay.
A separate ancestry-based BRCA testing initiative for eligible people with Westray or Whalsay ancestry is also planned in Scotland.
You can read more through the Viking Genes Westray and Whalsay BRCA screening project.
These programmes show why ancestry can sometimes help identify inherited cancer risk even when family history doesn’t provide an obvious warning.
What happens if an inherited prostate cancer risk is found?
Finding an inherited cancer-risk variant can feel worrying, particularly if you’ve seen relatives go through cancer treatment.
But knowing about inherited risk can also create opportunities for earlier detection, more personalised care and testing for other family members.
Earlier prostate cancer screening
In 2026, the UK National Screening Committee recommended a new targeted prostate screening programme for a specific group of men at increased inherited risk.
The recommendation is for men aged 45 to 61 who carry a confirmed disease-causing BRCA2 variant and also have a family history of breast, ovarian, pancreatic or prostate cancer.
These men would be offered a PSA blood test every two years.
The UK government has accepted this recommendation for England, with rollout expected to begin in 2027.
This is an important development because it recognises that identifying inherited risk can help determine who is most likely to benefit from prostate cancer screening.
However, the new programme is not yet fully operational, and it doesn’t apply to everyone with a family history of prostate cancer.
For men already known to carry a pathogenic BRCA2 variant, existing specialist guidance supports discussing annual PSA testing from age 40. If this applies to you, ask your GP or genetics team about the current arrangements rather than waiting for the new programme.
Does everyone need regular PSA testing?
Not necessarily.
A PSA test measures prostate-specific antigen in the blood. Higher levels can sometimes be associated with prostate cancer, but PSA can also rise for other reasons, including benign prostate enlargement and inflammation.
PSA testing can help find some prostate cancers earlier, but it can also lead to false alarms, unnecessary investigations and treatment of cancers that might never have caused harm.
This is why routine population-wide PSA screening isn’t currently recommended in the UK.
Men who are concerned about their risk can discuss the benefits and limitations of PSA testing with their GP. At Coyne Medical, we offer PSA testing for all males at our health screening appointments, after a discussion with their doctor.
More personalised treatment
For someone who already has prostate cancer, knowing whether they carry certain inherited genetic changes may also influence treatment options.
For example, some prostate cancers with BRCA-related DNA repair defects may be eligible for treatments such as PARP inhibitors, depending on the stage of the cancer and the relevant NHS treatment criteria.
It’s important to distinguish testing the cancer itself from testing for an inherited genetic change.
A genetic change found in a tumour isn’t always inherited, so additional testing may sometimes be needed to clarify this.
Testing other family members
If an inherited gene change is identified, adult relatives can usually be offered targeted testing to find out whether they carry the same variant.
This can be relevant to men and women.
For example, finding a BRCA2 variant in a man with prostate cancer could help identify female relatives who may benefit from earlier breast screening, as well as male relatives who may benefit from a discussion about prostate cancer risk.
Finding an inherited cancer-risk gene doesn’t mean you’ll definitely develop cancer. It means you have more information and more choices about your future health.
What should I ask my NHS GP?
If your father, brother, grandfather or another relative has had prostate cancer, it’s worth asking whether your family history changes your own risk.
You don’t need to know which genes might be involved or arrive with a complete family tree.
You could simply say:
“My dad/brother had prostate cancer, and I’m wondering whether there could be an inherited risk in our family. Would it be worth reviewing our family history or referring us for genetic assessment?”
Before your appointment, try to find out:
- Which relatives have had prostate cancer, on either side of your family.
- Roughly how old they were when diagnosed.
- Whether the cancer was described as aggressive or had spread beyond the prostate.
- Whether there have been breast, ovarian, pancreatic, bowel or womb cancers in the family.
- Whether anyone has already had genetic testing, and what the result showed.
- Whether there is any relevant ancestry, including Jewish or Whalsay ancestry.
If someone in your family who has had prostate cancer is available for testing, it may be more helpful to investigate them first.
If you don’t meet NHS genetic testing criteria, you can still ask your GP about your individual prostate cancer risk and whether a PSA test would be appropriate.
Our family history of cancer guide explains what information to collect and why it matters.
Frequently Asked Questions
Not necessarily.
Prostate cancer is common, particularly in older men, so having one affected relative doesn’t always suggest an inherited high-risk gene.
However, the age when your father was diagnosed, whether his cancer was aggressive and other cancers in your family can all make a difference.
It’s worth discussing the family history with your GP or a genetic testing clinic.
Yes. Grandparents are second-degree relatives, and their cancer history can be relevant.
The importance depends on the age at diagnosis, other affected relatives and the overall family history.
Absolutely.
A man can inherit a BRCA2 or other cancer-risk variant from his mother even if she has never had cancer herself.
This is why breast and ovarian cancer in your mother’s family may be relevant to your prostate cancer risk.
No.
Most prostate cancers, including many aggressive cancers, aren’t caused by an identified inherited BRCA2 variant.
However, aggressive or metastatic disease, particularly at a younger age, can make inherited genetic testing more relevant.
Yes.
Families may be small, medical histories may be unknown, or a genetic change may have been passed down through relatives who never developed cancer.
A lack of family history doesn’t completely rule out inherited risk.
It’s worth discussing with your GP.
Having a father or brother with prostate cancer can increase your risk, but PSA screening has benefits and limitations.
Your age, family history, ethnicity, symptoms and any known inherited genetic changes should all be considered when making a decision.
No. They answer different questions.
Genetic testing looks for inherited changes that may increase your future cancer risk.
A PSA test looks for a blood marker that can sometimes indicate prostate disease, including cancer.
Having genetic testing can help inform decisions about screening, but it doesn’t replace PSA testing or assessment of symptoms.
No.
Most prostate cancers occur in men without an identified inherited high-risk variant.
A negative result doesn’t remove your risk, and your age, family history and other factors may still be relevant.
Yes.
Women can inherit and pass on variants in genes such as BRCA1 and BRCA2.
These genes can also increase the risk of breast, ovarian and other cancers, so identifying inherited prostate cancer risk in a family can have important implications for female relatives.
Yes.
Private inherited cancer genetic testing is available to people who don’t meet NHS eligibility criteria, including some people who have never had cancer.
A doctor consultation before testing can help you understand whether testing is useful, which genes should be considered and what the results might mean for you and your family.
Genetic testing referrals for healthcare professionals
If you’re a urologist, oncologist, physician or another healthcare professional caring for patients concerned about inherited prostate cancer risk, we can help.
Prostate cancer can sometimes be part of a wider inherited cancer pattern, particularly where there is a family history of breast, ovarian or pancreatic cancer.
Some patients may not meet NHS or insurance criteria for inherited genetic testing, while others may want to understand their risk more fully before they develop cancer.
At Coyne Medical, we work alongside consultants who want to include genetic testing as part of their patients’ preventative care.
Our doctor-led 36-gene inherited cancer panel includes BRCA1, BRCA2 and other genes relevant to inherited cancer risk. Testing is performed by a UKAS-accredited UK laboratory that also supports NHS genetic testing.
Every patient has a doctor consultation before testing and a scheduled follow-up, whether their result is positive or negative.
We can help interpret the findings, discuss appropriate prevention and screening, and coordinate NHS or private specialist referrals where appropriate.
With the patient’s consent, we can also share results and recommendations with their referring clinician.
We work alongside you, helping you offer your patients more comprehensive preventative care.
What should you do if prostate cancer runs in your family?
If your dad, brother, grandfather or another relative has had prostate cancer, it’s worth considering whether there could be an inherited risk.
Start by checking who may qualify for NHS inherited cancer genetic testing.
It can also help to collect information about the types of cancer in your family and the ages when relatives were diagnosed. Our family history of cancer guide explains how to get started.
And remember, you don’t need a strong family history of cancer to carry an inherited cancer-risk gene.
Finding risk earlier creates choices
At Coyne Medical, we believe that understanding inherited cancer risk can help people make more informed decisions about their future health.
Our doctor-led 36-gene inherited cancer panel includes BRCA1, BRCA2 and other genes associated with increased cancer risk.
Every patient has a consultation before testing and a follow-up appointment to explain their results, discuss screening and prevention, and help arrange specialist referrals where appropriate.
Even when testing doesn’t identify an inherited gene change, we’ll consider your personal and family history and what that may mean for your future health.
DR LUCY HOOPER
MB BS BSc MRCGP MA DRCOG DCH
Lucy is a GP and co-founder of Coyne Medical. She graduated with honours from Imperial College London, trained at St Mary’s Hospital, and holds a Master’s in Medical Ethics and Law. Her clinical interests span women’s health, preventive medicine, and genomics, with a particular focus on using advanced biomarkers to build a more complete picture of long-term health.
British Society for Genetic Medicine · European Atherosclerosis Society ·
Independent Doctors Federation
As seen in BBC, The Guardian, Women’s Health, The Times and Tatler
For educational purposes. This article is written by a practising GP and is intended to inform, not replace a consultation with your own doctor. It does not constitute medical advice. A note on clinical guidelines: Coyne Medical is an independent private clinic. Our approach is guided by the best available evidence, tailored to each individual. This may go beyond standard NHS or NICE guidance, which is designed for population-level care and weighted by resource constraints.
References
- NHS England National Genomic Test Directory. The April 2026 R430 criteria include diagnosis under 50, metastatic disease under 60, specified ancestry and specialist risk assessment. england.nhs.uk
- NHS Genomics Education: Family history of prostate cancer. In the Clinic
- NHS Genomics Education: Genetic testing in prostate cancer. In the Clinic
- UK National Screening Committee: Prostate screening recommendation. GOV.UK
- Department of Health: June 2026 targeted prostate screening announcement.
Medically reviewed by Dr Lucy Hooper MB BS BSc MRCGP MA DRCOG DCH. Review date: 29th October 2026.
This article provides general information and is not a substitute for personalised medical advice. NHS eligibility criteria and testing programmes may change. If you are concerned about your personal or family history, discuss it with your GP or specialist.